common side effects of actos
upper respiratory tract infection
edema
hypoglycemia
other side effects
cardiac failure
exacerbation of congestive heart failure
bone fracture
headache
pharyngitis
comprehensive list of adverse effects
edemacommon
congestive heart failure
including
fatal cases
cardiac failure
chest pain
proactive trial
study in patients with type diabetes
history of macrovascular disease
pioglitazone mg
day
given placebo in addition
standard of care
edema
patients
pioglitazone
n =-rrb-
placebo
n =-rrb- patients
treatment-emergent adverse events
least hospitalized congestive heart failure event
patients
receiving pioglitazone
patients
receiving placebo
primary objective of the
year
proactive trial
effect of pioglitazone on mortality
macrovascular morbidity in high-risk patients
significant difference between pioglitazone
placebo/standard care
time
first occurrence
first event
all-cause mortality
nonfatal myocardial infarction
mi
including
silent mi
stroke
acute coronary syndrome
cardiac intervention
coronary artery bypass grafting
percutaneous intervention
major leg amputation above the ankle
bypass surgery
revascularization in the leg
total of patients
receiving pioglitazone
least event
patients
receiving placebo/standard care
pioglitazone
edema
pitting edema
fluid retention
combination therapy
pioglitazone monotherapy trials
edema
n =-rrb-
n =-rrb-
n =-rrb- of patients
receiving mg
mg
mg of pioglitazone
weeks
pioglitazone in combination with a sulfonylurea
weeks
edema
n =-rrb-
n =-rrb-
n =-rrb- of patients
receiving mg
mg
mg of pioglitazone
study in patients with nyha class
heart failure
percentage of patients
experiencing chf progression during the study
patients
receiving pioglitazone
n =-rrb-
glyburide
n =-rrb-
postmarketing reports of congestive heart failure
patients
pioglitazone
reports
patients
history of a known history of heart disease
concomitant insulin use
frequency
hypersensitivity
allergic reactions
hypoglycemia
weight
reported side effects
hypoglycemia
weight
edema
upper respiratory tract infection
frequency
small reduction in mean hemoglobin
hematocrit
visual disturbance
abnormal visionfrequency
macular edema
visual disturbances
treatment
changes in blood glucose
temporary alteration in the turgidity
refractive index of the lens
macular edema
been reported postmarketing in patients
taking pioglitazone
patients
blurred vision
decreased visual acuity
routine ophthalmologic examination
most patients
peripheral edema at time of diagnosis
patients
drug discontinuation
postmarketing reports of fatal
nonfatal hepatic failure
patients
drug
reports
causality
clinical trials
evidence of drug-induced hepatotoxicity
increased alanine aminotransferasefrequency
decreased mean values of bilirubin
ast
alkaline phosphatase
ggtpostmarketing reports
nonfatal hepatic failure
hepatocellular dysfunction
fatigue
accidental injury
peripheral edema
asthenia
malaise
tooth disorder
tooth abscess
gastroenteritis
diarrhea
upper abdominal pain
urinary tract infection
fractures
myalgia
pain in extremity
pain
cramped legs
arthralgia
prospective pioglitazone
clinical trial in macrovascular events
incidence of bone fractures in female patients with this drug
placebo
treated patients
majority of fractures
nonvertebral including
lower limb
distal upper limb
incidence in men
placebo
headache
hypoesthesia
insomnia
upper
respiratory tract infection
sinusitis
pharyngitis
bronchitis
influenza
us fda
released results
review of pioglitazone
active ingredient
actos
bladder cancer
data
use of this drug
increase risk of bladder cancer
year
prospective cohort study in diabetic patients
manufacturer
n
users
n
users
diagnosed cases of bladder cancer
users
cases
users
adjusted hazard ratio
hr
pioglitazone use
increased risk
hr
confidence interval
modest trend towards higher risk
increasing duration
trend
interim
year
year
found weaker associations
studies
significant association between exposure
drug
bladder cancer
association between cumulative dose
cumulative duration of exposure
bladder cancer
drug
increase in the risk of urinary bladder tumors
insufficient data
drug
tumor promoter for urinary bladder tumors
bladder cancer
chest pain
decreased urine output
dilated neck veins
extreme fatigue
irregular breathing
irregular heartbeat
problems with teeth
shortness of breath
swelling of the face
fingers
feet
lower legs
tightness in the chest
trouble with breathing
weight gain
wheezing
pain
swelling in the arms
legs without an injury
pale skin
swelling
trouble with breathing
unusual bleeding
bruising
unusual tiredness
weakness
dark urine
loss of appetite
nausea or vomiting
stomach pain
rapid weight gain
yellow eyes
skin
blurred vision
other changes in vision
cough
dry mouth
flushed, dry skin
fruit-like breath odor
headache
increased hunger
increased thirst
increased urination
loss of consciousness
muscle pain
soreness
problems
teeth
stuffy nose
sore throat
stomachache
sweating
unexplained weight loss